StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Ansh Jogendra Bhilwar

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byAnsh Jogendra BhilwarHorizon: NA (inferred Swing (≤2wk))27 Aug 2026via Zee Business (Live)

Entry₹1,160Inferred
Target₹1,245
Total upside +7.33% (call closed)
Stop loss₹1,104-4.83% risk
At expiry₹1,127.49 Sept 2026, 3:30 pm
Expired-2.81%auction close
Follow Ansh Jogendra Bhilwar for new calls(25% target hit, 52 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 3 active Swing calls on ZYDUSLIFESee 169 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 9 Sept 2026
8 supporting1 neutral0 opposing
Supports the BUY call (8)

India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth

NewsNdtv-Profit·9 Sept · today

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·7 Sept · yesterday

Zydus Lifesciences announced positive topline results from the completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg for MASH.

BSE · Company Update·31 Aug · 1w ago

(opens in new tab)

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

NewsNdtv-Profit·27 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection

NewsNdtv-Profit·21 Aug · 3w ago

(opens in new tab)
Neutral / worth noting (1)

Zydus Pharmaceuticals USA Inc., a subsidiary of Zydus Lifesciences, has agreed to pay USD 5.9 million to settle litigation in the US District Court for the Eastern District of Pennsylvania. The settle

BSE · Company Update·5 Sept · 3d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Ansh Jogendra Bhilwar

Every call and its outcome